The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable?
Open accessAbstract
BACKGROUND: Evaluation of response to treatment is a key aspect in cancer therapy. Response Evaluation Criteria in Solid Tumors (RECIST) are used in most oncology trials, but those criteria evaluate only unidimensional tumor measurements and disregard the extent of necrosis, which is the target of all effective locoregional therapies. Therefore, the European Association for the Study of the Liver (EASL) guidelines recommended that assessment of tumor response should incorporate the reduction in viable tumor burden. The current report provides an assessment of the agreement/concordance between both RECIST and the EASL guidelines for the evaluation of response to therapy. METHODS: The authors evaluated a cohort of 55 patients within prospective studies, including 24 patients with hepatocellular carcinoma who underwent transarterial chemoembolization (TACE) with drug eluting beads (DEB‐TACE) and 31 patients who underwent percutaneous ablation (percutaneous ethanol injection [PEI]/radiofrequency [RF]). Triphasic helical computed tomography scans were performed at baseline, at 1 month, and at 3 months after procedure, and 2 independent radiologists evaluated tumor response. RESULTS: Evaluating response according to RECIST criteria, no patients achieved a complete response (CR), 21.8% of patients achieved a partial response (PR) (none in the PEI/RF group), 47.3% of patients had stable disease (SD), and 30.9% of patients had progressive disease (PD). When response was evaluated according to the EASL guidelines, 54.5% of patients achieved a CR, 27.3% of patients achieved a PR, 3.6% of patients had SD, and 14.5% had PD. The κ coefficient was 0.193 (95% confidence interval, 0.0893‐0.2967; P < .0001). CONCLUSIONS: RECIST missed all CRs and underestimated the extent of partial tumor response because of tissue necrosis, wrongly assessing the therapeutic efficacy of locoregional therapies. This evaluation should incorporate the reduction in viable tumor burden as recognized by nonenhanced areas on dynamic imaging studies. Cancer, 2009. © 2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationBevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationTemsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Llovet, J. M., Real, M. I., Montaña, X., Planas, R., Coll, S., Aponte, J., Ayuso, C., Sala, M., Muchart, J., Solà, R., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08649-x · Cited by 3,494
Self-citationLlovet, J. M., & Bruix, J. (2003) · Hepatology · doi:10.1053/jhep.2003.50047 · Cited by 3,029
Self-citation
Cited by
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Lencioni, R., & Llovet, J. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1247132 · Cited by 4,329
Self-citationFrom RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
Image-guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Ahmed, M., Solbiati, L., Brace, C. L., Breen, D. J., Callstrom, M. R., Charboneau, J. W., Chen, M.-H., Choi, B. I., de Baère, T., Dodd, G. D., et al. (2014) · Radiology · doi:10.1148/radiol.14132958 · Cited by 1,346
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Llovet, J. M., De Baere, T., Kulik, L., Haber, P. K., Greten, T. F., Meyer, T., & Lencioni, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00395-0 · Cited by 1,044
Self-citationRecent progress in understanding, diagnosing, and treating hepatocellular carcinoma
Maluccio, M., & Covey, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21161 · Cited by 840
Multimodal treatment of hepatocellular carcinoma on cirrhosis: An update
Vivarelli, M. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i42.7316 · Cited by 799
mRECIST for HCC: Performance and novel refinements
Llovet, J. M., & Lencioni, R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 680
Self-citationSalem, R., Lewandowski, R. J., Kulik, L., Wang, E., Riaz, A., Ryu, R. K., Sato, K. T., Gupta, R., Nikolaidis, P., Miller, F. H., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.10.049 · Cited by 650
Raoul, J.-L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.002 · Cited by 643
Self-citationGarin, E., Tselikas, L., Guiu, B., Chalaye, J., Edeline, J., de Baere, T., Assenat, E., Tacher, V., Robert, C., Terroir-Cassou-Mounat, M., et al. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30290-9 · Cited by 630
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Self-citationImage-Guided Tumor Ablation: Standardization of Terminology and Reporting Criteria—A 10-Year Update
Ahmed, M., Solbiati, L., Brace, C. L., Breen, D. J., Callstrom, M. R., Charboneau, J. W., Chen, M.-H., Choi, B. I., de Baère, T., Dodd, G. D., et al. (2014) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.08.027 · Cited by 583
Lewandowski, R. J., Kulik, L. M., Riaz, A., Senthilnathan, S., Mulcahy, M. F., Ryu, R. K., Ibrahim, S. M., Sato, K. T., Baker, T., Miller, F. H., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02695.x · Cited by 582
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Raoul, J.-L., Sangro, B., Forner, A., Mazzaferro, V., Piscaglia, F., Bolondi, L., & Lencioni, R. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.07.006 · Cited by 537
Self-citationLocal-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Treatment of intermediate-stage hepatocellular carcinoma
Forner, A., Gilabert, M., Bruix, J., & Raoul, J.-L. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.122 · Cited by 466
Self-citationKorean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Systemic treatment of hepatocellular carcinoma: An EASL position paper
Bruix, J., Chan, S. L., Galle, P. R., Rimassa, L., & Sangro, B. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.004 · Cited by 380
Self-citationYttrium-90 microspheres for the treatment of hepatocellular carcinoma
Geschwind, J. F. H., Salem, R., Carr, B. I., Soulen, M. C., Thurston, K. G., Goin, K. A., van Buskirk, M., Roberts, C. A., & Goin, J. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.034 · Cited by 355
Iavarone, M., Cabibbo, G., Piscaglia, F., Zavaglia, C., Grieco, A., Villa, E., Cammà, C., & Colombo, M. (2010) · Hepatology · doi:10.1002/hep.24644 · Cited by 352
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Transarterial chemoembolization: Modalities, indication, and patient selection
Sieghart, W., Hucke, F., & Peck-Radosavljevic, M. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.010 · Cited by 336
Gillmore, R., Stuart, S., Kirkwood, A., Hameeduddin, A., Woodward, N., Burroughs, A. K., & Meyer, T. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.03.007 · Cited by 324
Positron Emission Tomography (PET) in Oncology
Gallamini, A., Zwarthoed, C., & Borra, A. (2014) · Cancers · doi:10.3390/cancers6041821 · Cited by 312
Garin, E., Lenoir, L., Rolland, Y., Edeline, J., Mesbah, H., Laffont, S., Porée, P., Clément, B., Raoul, J.-L., & Boucher, E. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.094235 · Cited by 283
Response Criteria in Oncologic Imaging: Review of Traditional and New Criteria
Tirkes, T., Hollar, M. A., Tann, M., Kohli, M. D., Akisik, F., & Sandrasegaran, K. (2013) · RadioGraphics · doi:10.1148/rg.335125214 · Cited by 279
Edeline, J., Boucher, E., Rolland, Y., Vauléon, E., Pracht, M., Perrin, C., Le Roux, C., & Raoul, J. (2012) · Cancer · doi:10.1002/cncr.26255 · Cited by 275
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Transcatheter Therapy for Hepatic Malignancy: Standardization of Terminology and Reporting Criteria
Brown, D. B., Gould, J. E., Gervais, D. A., Goldberg, S. N., Murthy, R., Millward, S. F., Rilling, W. S., Geschwind, J.-F. S., Salem, R., Vedantham, S., et al. (2009) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2009.04.021 · Cited by 257
Metadata
- Authors
- Forner, A., Ayuso, C., Varela, M., Rimola, J., Hessheimer, A. J., de Lope, C. R., Reig, M., Bianchi, L., Llovet, J. M., & Bruix, J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-01-20
- Volume
- 115
- Issue
- 3
- Pages
- 616-623
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2024029636
- Cited by
- 426
- References
- 34
- FWCI
- 16.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.